Colorectal Cancer (CRC) Active Not Recruiting Phase 2 Trials for Atezolizumab (DB11595)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Active Not Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT06784947	Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer	Treatment	Atezolizumab (DB11595) Bevacizumab (DB00112) Tiragolumab (DB16409)
NCT05999812	Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer	Treatment	Atezolizumab (DB11595) Bevacizumab (DB00112) Tretinoin (DB00755)
NCT05118724	Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin	Treatment	Atezolizumab (DB11595) IMM-101 (DB15850)
NCT03228667	QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors	Treatment	Atezolizumab (DB11595) Avelumab (DB11945) Docetaxel (DB01248) Durvalumab (DB11714) Inbakicept (DB16479) Nivolumab (DB09035) Nogapendekin alfa (DB18740) PD-L1 t-haNK (DB23689) Pembrolizumab (DB09037)